MENS
Jyong Biotech Ltd. Ordinary Shares
NASDAQ · Healthcare · Biotechnology · TW
$2.39
+5.29%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 58.0K | 100.0K | 120.0K | 127.0K | 122.0K |
| Gross Profit | (58.0K) | (100.0K) | (120.0K) | (127.0K) | (122.0K) |
| Operating Expenses | |||||
| R&D Expense | 813.4K | 731.0K | 927.0K | 1.1M | 1.3M |
| SG&A Expense | 1.8M | 1.8M | 1.1M | 1.7M | 1.5M |
| General & Admin Expense | 987.00 | — | 1.1M | 1.7M | 1.5M |
| Selling & Marketing Expense | 24.00 | — | 44.0K | 47.0K | 47.0K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.6M | 2.5M | 2.1M | 2.8M | 2.8M |
| Cost and Expenses | 2.6M | 2.6M | 2.1M | 2.8M | 2.8M |
| Operating Income (EBIT) | (2.6M) | (2.6M) | (2.1M) | (2.8M) | (2.8M) |
| Non-Operating | |||||
| Interest Income | 611.0K | 610.0K | 7.0K | 56.0K | 5.0K |
| Interest Expense | 3.1M | 2.5M | 1.0M | 757.0K | 765.0K |
| Net Interest Income | (1.9M) | (1.9M) | (1.0M) | (701.0K) | (760.0K) |
| Other Non-Op Income/Expense | (2.1M) | (2.1M) | (963.0K) | (1.6M) | (3.8M) |
| Non-Operating Income (excl Interest) | 19.0K | — | (72.0K) | 846.0K | 3.0M |
| EBT (Pre-Tax Income) | (4.7M) | (4.7M) | (3.0M) | (4.4M) | (6.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (4.7M) | (4.7M) | (3.0M) | (4.4M) | (6.6M) |
| Earnings from Cont. Ops | (4.7M) | (4.7M) | (3.0M) | (4.4M) | (6.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (4.7M) | (4.7M) | (3.0M) | (4.4M) | (6.6M) |
| Per Share | |||||
| Basic EPS | ($0.10) | ($0.06) | ($0.04) | ($0.06) | ($0.09) |
| Diluted EPS | ($0.10) | ($0.06) | ($0.04) | ($0.06) | ($0.09) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 74.2M | 73.0M | 76.0M | 76.0M | 76.0M |
| Diluted Shares Outstanding | 74.2M | 73.0M | 76.0M | 76.0M | 76.0M |
| Profitability Metrics | |||||
| EBITDA | (2.6M) | (2.5M) | (1.9M) | (3.5M) | (5.7M) |
| D&A | 59.00 | 100.0K | 120.0K | 127.0K | 123.0K |
| EBIT | (2.6M) | (2.6M) | (2.0M) | (3.6M) | (5.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025